Alecensa may be the new first-line therapy for some patients with lung cancer, after a recent study yielded promising results for the drug. Patients with advanced or recurrent ALK-positive non—small ...
Treatment with Libtayo may improve survival over a 30-month period with no new side effects in patients with recurrent or metastatic cervical cancer, opening the doors for an immunotherapy option for ...
Simultaneous Chemoradiotherapy Compared With Radiotherapy Alone After Induction Chemotherapy in Inoperable Stage IIIA or IIIB Non–Small-Cell Lung Cancer: Study CTRT99/97 by the Bronchial Carcinoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results